Therefore, ACE2 could offer protection to the lungs and heart against injuries, indicating an obliteration of ACE2 protection in COVID-19 patients, along with the concomitant development of cardiovascular complications and the loss of renal function, especially in hospitalized patients [41]. This evidence concerns the gene ACE2 and COVID-19.